Here’s What the Street is Saying About Amgen Inc. (AMGN)

The standing update came the aforesaid time Amgen Inc. (NASDAQ:AMGN) announced that the European Commission’s support of UPLIZNA® arsenic an add-on attraction to modular therapy for adults surviving with generalized myasthenia gravis who are anti-acetylcholine receptor oregon anti-muscle-specific tyrosine kinase antibody positive. Management stated that the support provides patients with a caller and targeted attraction option, and holds the imaginable for semipermanent illness power done twice-yearly attraction dosing, pursuing 2 archetypal loading doses.

Amgen Inc. (NASDAQ:AMGN) besides reported its fiscal Q4 and full-year 2025 results connected February 3, announcing beardown show successful 2025 with double-digit maturation successful revenues and EPS. Total revenues for fiscal Q4 roseate 9% to $9.9 cardinal compared to the anterior twelvemonth period, with merchandise income increasing 7%, driven by 10% measurement growth. Total revenues for the afloat twelvemonth reached $36.8 billion, up 10% compared to the aforesaid 4th past year.

Amgen Inc. (NASDAQ:AMGN) is simply a biotechnology institution that discovers, develops, manufactures, and markets quality therapeutics. It delivers caller therapies for patients with analyzable cancers, particularly successful areas with important unmet needs.

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.